GlassScriptPhysician profile
Donna P Denier
NPI 1225038060
$4,564.51
in general payments reported to CMS, 2019-2025
32 companies · $411 in 2025
The $411 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $839 · 2021: $356 · 2022: $105 · 2023: $693 · 2024: $800 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.40 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,044.23 | 2019-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $529.68 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $503.09 | 2019-2025 | |
| Amgen INC. | $428.89 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $191.42 | 2019-2022 | |
| Boston Scientific Corporation | $182.99 | 2019-2024 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $157.86 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $129.59 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $121.25 | 2024 | (Cm9) Amb Mon & Diag Und, (Ck4) Mcot |
| Novartis Pharmaceuticals Corporation | $119.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.70 | 2019-2022 | |
| Inari Medical, INC. | $116.74 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $93.78 | 2021-2024 | Verquvo |
| Novo Nordisk INC | $87.03 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $79.16 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $71.18 | 2019-2020 | |
| Edwards Lifesciences Corporation | $65.55 | 2025 | Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $55.02 | 2024-2025 | |
| Abiomed | $54.38 | 2025 | |
| Irhythm Technologies, INC. | $52.63 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Ge Healthcare | $51.74 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.36 | 2019-2024 | Camzyos |
| Biosense Webster, INC. | $45.15 | 2023 | Carto 3 |
| Regeneron Healthcare Solutions, INC. | $38.47 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $38.38 | 2024 | Arcalyst |
| Baxter Healthcare | $36.51 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $28.17 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.27 | 2022 | |
| Amarin Pharma, INC. | $17.71 | 2019 | |
| Astellas Pharma US INC | $14.84 | 2019 | |
| Infobionic, INC | $14.58 | 2020 | |
| Portola Pharmaceuticals, LLC | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Denier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.